Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 11/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.34 |
| ▸ | VHL | P40337 | 1/20 | 0.33 |
| ▸ | ELOC | Q15369 | 1/20 | 0.33 |
| ▸ | ELOB | Q15370 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372829 | 0.90 | USP30 (0.40) | UCHL1USP30VHLELOCELOB | |
| SCHEMBL17212628 | 0.90 | USP30 (0.40) | UCHL1USP30VHLELOCELOB | |
| SCHEMBL2372832 | 0.90 | USP30 (0.40) | UCHL1USP30VHLELOCELOB | |
| SCHEMBL16577461 | 0.90 | USP30 (0.40) | UCHL1USP30VHLELOCELOB | |
| SCHEMBL2452351 | 0.89 | USP30 (0.39) | UCHL1USP30VHLELOCELOB | |
| SCHEMBL15773778 | 0.89 | USP30 (0.39) | UCHL1USP30VHLELOCELOB | |
| SCHEMBL12682646 | 0.85 | UCHL1 (0.45) | UCHL1HCRTR1HCRTR2HTT | |
| SCHEMBL2381124 | 0.84 | USP30 (0.42) | UCHL1USP30PRMT5WDR77HTT | |
| SCHEMBL2381126 | 0.84 | USP30 (0.42) | UCHL1USP30PRMT5WDR77HTT | |
| SCHEMBL14914418 | 0.84 | UCHL1 (0.44) | UCHL1HCRTR1HCRTR2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773634-B1 | ROD-LIKE HEPATITIS C VIRUS INHIBITORS CONTAINING THE FRAGEMENT {2-[4-(BIPHENYL-4-YL)-1H-IMIDAZO-2-YL]PYRROLIDINE-1-CARBONLYMETHYL}AMINE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9669027-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-9212168-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-15 | — | — | US | disclosed |
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | UCHL1 3040/4885USP30 2866/4885HCRTR1 3742/4885 |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | UCHL1 3040/4885USP30 2866/4885HCRTR1 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.